Anavex Life Sciences Corp (AVXL)

[nidan7500]

Moving forward and looking better with each passing day

Exactly correct. Would like to think AVXL team has done sufficiently complete Genomic analysis of the Aussie trial patients thereby providing evidence in retrospect of who responded and how much. Even the precision medicine differences between those who responded robustly and those that responded less becomes critically important going forward. Knowing the exact differences between these distributed populations may be possible and may be critical in CNS diagnostics going forward.

IMO, we should also note the references made about continuously improving Aussie patients. Not much has been mentioned here on this topic but it is possible and additional extension of the trial w/all involved is a good sign. So to speak, that is the opposite of the Amyloid AD efforts of the past.